Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study. In a study comparing deucravacitinib ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color. Guselkumab shows rapid and significant ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

Plaque PsO is an immune-mediated disease resulting in the overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that eight million Americans ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Please provide your email address to receive an email when new articles are posted on . At week 16, 49.4% of the tildrakizumab group achieved clearance or near clearance of their scalp psoriasis vs. 7 ...

Psoriasis and dandruff are both fairly common scalp conditions and are often confused. Somewhere between 2 and 3 percent of the population has psoriasis, and about half of these people have scalp ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Scalp Psoriasis vs. Dandruff: What’s the Difference? This article was reviewed by Knox Beasley, MD. If you’re experiencing a flaking, itching scalp, you may do a quick self-diagnosis of dandruff. But ...